Add BrightSurf on Google Email

Common antidepressants could help the immune system fight cancer, UCLA study finds

A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...

New study advances cancer precision therapies by identifying patients who benefit from Bexmarilimab treatment

A new study at the University of Turku identified conditions under which Bexmarilimab activates the immune system against cancer. The drug was shown to trigger B cell-mediated immune responses in healthy tissue adjacent to tumors. This could lead to more accurate patient selection and improved treatment outcomes.

SourceUniversity of Turku·JournalJournal for ImmunoTherapy of Cancer·DateMay 20, 2025

Modification makes immunotherapy for blood cancer even more effective

Researchers at A.C.Camargo Cancer Center developed a more powerful version of CAR-T cells by inhibiting the epigenetic alterations that made them inefficient against non-Hodgkin's lymphoma and acute lymphoblastic leukemia. This modification resulted in improved treatment efficacy, tumor elimination, and reduced side effects.

Rediscovering denosumab: From osteoporosis treatment towards a possible role against breast cancer

Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalBreast Cancer Research·TypeRandomized controlled/clinical trial·DateMay 16, 2025

New gene-editing therapy shows early success in fighting advanced GI cancers

Researchers have successfully tested a CRISPR/Cas9 gene-editing technique to enhance the immune system's fight against advanced gastrointestinal (GI) cancers. The treatment showed encouraging signs of safety and potential effectiveness in patients with stage IV colorectal cancer, halting tumor growth and even achieving complete responses.

SourceUniversity of Minnesota Medical School·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateMay 2, 2025

Some patients may experience durable disease control even after discontinuing immune checkpoint inhibitors for side effects

A subset of patients with non-small cell lung cancer who discontinued immune checkpoint inhibitor therapy due to immune-related adverse events continued to experience long-term disease control. The median post-discontinuation progression-free survival was 12.7 months, and the median post-discontinuation overall survival was 43.7 months.

SourceAmerican Association for Cancer Research·JournalClinical Cancer Research·DateApr 18, 2025

A type of immune cell strengthens immunotherapy and prevents tumor relapse in animal models

Scientists have discovered a new immunotherapy strategy using type I dendritic cells to activate strong immune responses and generate immune memory against cancer. The treatment helps prevent tumor relapse in mouse models by triggering an immune memory response.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalNature Communications·TypeExperimental study·DateApr 15, 2025

KAIST identifies master regulator blocking immunotherapy, paving the way for a new lung cancer treatment​

Researchers at KAIST discovered that DDX54 is the master regulator hindering immunotherapy's effectiveness in lung cancer. Supressing DDX54 enhances immune cell infiltration into tumors and improves immunotherapy efficacy.

SourceThe Korea Advanced Institute of Science and Technology (KAIST)·JournalProceedings of the National Academy of Sciences·TypeRandomized controlled/clinical trial·DateApr 9, 2025

Driving the CAR to fight acute myeloid leukemia

Researchers at Osaka University identify a specific molecule, HLA-DRB1, that can be targeted by CAR-based therapy for AML. Engineered CAR T cells showed strong and specific anti-AML effects in vitro and in vivo with mice, without overt toxicity.

SourceOsaka University·JournalNature Cancer·TypeExperimental study·DateApr 1, 2025

Getting cancer to unmask itself

Researchers from Prof. Yardena Samuels's lab developed a new approach to cancer treatment by manipulating cancer cells to produce dozens of suspicious proteins, leading to a powerful immune response that destroys human cancer cells and slows tumor growth in mouse models.

SourceWeizmann Institute of Science·JournalCancer Cell·DateMar 31, 2025

CNIO research reveals how melanoma and other tumours succeed in hiding and resisting immunotherapy

A recent study by the CNIO Melanoma Group has discovered a mechanism by which melanomas evade immune system surveillance. The research found that melanoma cells secrete Midkine, a protein that reduces dendritic cell numbers and reprograms their function to promote tumour development.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalNature Cancer·TypeExperimental study·DateMar 28, 2025

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.

SourceUniversity of Pittsburgh·JournalScience Translational Medicine·DateMar 19, 2025

Dr. Theodore Scott Nowicki awarded $4.5M NCI grant to advance next generation of cellular immunotherapies for solid tumors

Dr. Nowicki's team has engineered 'supercharged' T cells that produce extra TNF-alpha to boost cancer-fighting ability, offering a potentially more precise and toxic-free treatment option. The new funding will help test these enhanced T cells in preclinical models to evaluate their effectiveness.

Combination immunotherapy before surgery may increase survival in people with head and neck cancer

Researchers at University of North Carolina Health Care found that combination immunotherapy before surgery increased survival rates in people with head and neck squamous cell carcinomas. The treatment regimen doubled or tripled the response rate versus single immunotherapy, leading to a survival benefit for up to a third of patients.

SourceUniversity of North Carolina Health Care·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateMar 13, 2025

Chemo-immunotherapy approach shows potential benefit in patients with advanced HPV-negative head and neck cancer

A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.

SourceUniversity of Chicago Medical Center·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateMar 6, 2025

Study reveals hope for immunotherapy as prostate cancer treatment

Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...

SourceUniversity of Arizona Health Sciences·JournalCancer Immunology Research·TypeExperimental study·DateMar 4, 2025

Rare side effect of cancer immunotherapy

A rare case of T cell lymphoma developed in a patient with multiple myeloma nine months after CAR-T cell therapy. Genetic alterations in the patient's haematopoietic cells played a role in tumour development, highlighting the importance of genetic predispositions for potential side effects.

SourceUniversität Leipzig·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateFeb 21, 2025

Lancet article details drug’s lack of benefit for head and neck cancer

A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.

SourceUniversity of Oklahoma·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateFeb 20, 2025